# A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients

> **NCT04179513** · PHASE1 · UNKNOWN · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** GB224 10mg
- **BIOLOGICAL:** GB224 20mg

## Key facts

- **NCT ID:** NCT04179513
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-15
- **Primary completion:** 2020-12
- **Final completion:** 2021-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179513, "A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04179513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*